Impact BioMedical Inc. (NYSEAM: IBO)
Health Care · Pharmaceuticals · US
$0.48
+4.51% today · -22.2% 1Y
Impact BioMedical Inc. (NYSEAM: IBO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $49.52M and employs 2 people.
Over the last twelve months the share price has lost 22.2%, trading between 0.37 and 0.83.
Tweenvest scores Impact BioMedical Inc. across four factors: quality 23/100, value 34/100. Its strongest factor is value.
IBO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $49.52M
- Revenue (TTM)
- $35.00K
- P/E
- 87.49
- EPS
- 0.01
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $0.83
- 52-week low
- $0.37
- Avg volume (3M)
- —
- Shares outstanding
- 107.82M
- Employees
- 2
- Next earnings
- —
About Impact BioMedical Inc.
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
- Founded
- 2018
- Listed since
- Sep 16, 2024
- Exchange
- NYSE American LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.